-
公开(公告)号：US20190233530A1
公开(公告)日：2019-08-01
申请号：US16379844
申请日：2019-04-10
Applicant: UCB BIOPHARMA SPRL , BIOGEN MA INC.
Inventor： Linda C. Burkly , Janine L. Ferrant-Orgettas , Ellen A. Garber , Yen-Ming Hsu , Lihe Su , Frederick R. Taylor , Ralph Adams , Derek Thomas Brown , Andrew George Popplewell , Martyn Kim Robinson , Anthony Shock , Kerry Louise Tyson
IPC: C07K16/28 , A61K39/395 , A61K45/06
CPC classification number: C07K16/2875 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/40 , C07K2317/52 , C07K2317/55 , C07K2317/71 , C07K2317/734 , C07K2317/76 , C07K2317/92
Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
-
公开(公告)号：US11466076B2
公开(公告)日：2022-10-11
申请号：US16098085
申请日：2017-04-28
Applicant: UCB BIOPHARMA SPRL
Inventor： Ralph Adams , Sam Philip Heywood
IPC: C07K16/00 , C07K16/18 , C07K14/76 , C07K14/765 , C07K16/06 , A61K39/395 , A61K39/00 , C07K16/46
Abstract: The present disclosure relates to a method of modulating the half-life of a binding domain specific to a serum carrier protein by mutating the sequence and a modulated binding domain specific to a serum carrier protein.
-
公开(公告)号：US20170275355A1
公开(公告)日：2017-09-28
申请号：US15476279
申请日：2017-03-31
Applicant: UCB BIOPHARMA SPRL
Inventor： Ralph Adams , Andrew George Popplewell , Stephen Edward Rapecki , Simon Peter Tickle
CPC classification number: C07K16/244 , A61K47/60 , A61K2039/505 , C07K16/464 , C07K2317/20 , C07K2317/24 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.
-
公开(公告)号：US20160039929A1
公开(公告)日：2016-02-11
申请号：US14795374
申请日：2015-07-09
Applicant: UCB Biopharma SPRL
Inventor： Richard Evan Gelinas , Mitra Choudhury Singhal , Yi Zhang , Andrew George Popplewell , Ralph Adams
IPC: C07K16/24
CPC classification number: A61K39/3955 , A61K2039/505 , C07K16/248 , C07K2316/96 , C07K2317/24 , C07K2317/34 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C12N15/11
Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of IL-6, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
Abstract translation: 本发明涉及对IL-6的抗原决定簇具有特异性的抗体分子，抗体分子的治疗用途以及产生所述抗体分子的方法。
-
公开(公告)号：US20180346561A1
公开(公告)日：2018-12-06
申请号：US15974407
申请日：2018-05-08
Applicant: UCB BIOPHARMA SPRL
Inventor： Ralph Adams , Terence Seward Baker , Alastair David Griffiths Lawson
IPC: C07K16/24
CPC classification number: C07K16/244 , C07K2317/33 , C07K2317/92
Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
-
Patent Agency Ranking
公开(公告)号：US09803004B2
公开(公告)日：2017-10-31
申请号：US14356181
申请日：2012-11-09
Applicant: UCB Biopharma SPRL
Inventor： Ralph Adams , Pallavi Bhatta , Sam Philip Heywood , David Paul Humphreys
CPC classification number: C07K16/18 , C07K16/2878 , C07K2317/24 , C07K2317/31 , C07K2317/55 , C07K2317/624 , C07K2317/92
Abstract: A serum albumin binding antibody or fragment thereof comprising a heavy chain variable domain having the sequence given in SEQ ID NO: 1 or SEQ ID NO:2 and/or comprising a light chain variable domain having the sequence given in SEQ ID NO:3 or SEQ ID NO:4, in particular comprising a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 1 and SEQ ID NO:3 or a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 2 and SEQ ID NO:4. The disclosure also extends to polynucleotides encoding the antibodies or fragments, vectors comprising same and host cells capable of expressing the polynucleotides. The disclosure further includes pharmaceutical compositions comprising the antibodies or fragments and therapeutic used of any one of the same.
-
公开(公告)号：US20150218271A1
公开(公告)日：2015-08-06
申请号：US14690892
申请日：2015-04-20
Applicant: UCB Biopharma SPRL
Inventor： Ralph Adams , Terence Seward Baker , Alastair David Griffiths Lawson
IPC: C07K16/24
CPC classification number: C07K16/244 , C07K2317/33 , C07K2317/92
Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
Abstract translation: 本发明涉及对IL-17A和IL-17F的抗原决定簇具有特异性的抗体分子，抗体分子的治疗用途和产生所述抗体分子的方法。
-
8.发明授权公开(公告)号：US10308723B2
公开(公告)日：2019-06-04
申请号：US15482260
申请日：2017-04-07
Applicant: UCB BIOPHARMA SPRL
Inventor： Ralph Adams , Andrew George Popplewell , Stephen Edward Rapecki
IPC: A61K39/395 , C07K16/46 , C07K16/24
Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
-
公开(公告)号：US09988446B2
公开(公告)日：2018-06-05
申请号：US14690892
申请日：2015-04-20
Applicant: UCB Biopharma SPRL
Inventor： Ralph Adams , Terence Seward Baker , Alastair David Griffiths Lawson
IPC: A61K39/395 , C07K16/24
CPC classification number: C07K16/244 , C07K2317/33 , C07K2317/92
Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
-
10.发明申请Anti-aP2 Antibodies and Antigen Binding Agents to Treat Metabolic Disorders 审中-公开抗αP2抗体和抗原结合剂治疗代谢紊乱公开(公告)号：US20160319003A1
公开(公告)日：2016-11-03
申请号：US15143162
申请日：2016-04-29
Inventor： Gökhan S. Hotamisligil , Mehmet F. Burak , Feyza Engin , Scott B. Widenmaier , Elisabeth Helen Roberts , Adrian Richard Moore , Carl Brendan Doyle , Ralph Adams , Karine Jeannine Madeleine Hervé , Shauna Mhairi Wales , Kerry Louise Tyson
IPC: C07K16/18
CPC classification number: C07K16/18 , A61K39/00 , A61K2039/505 , A61K2039/507 , A61K2039/6018 , C07K2317/24 , C07K2317/55 , C07K2317/565 , C07K2317/70 , C07K2317/76 , C07K2317/92
Abstract: This invention is in the area of improved anti-aP2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone aP2/FABP4 (referred to as “aP2”) for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and/or cancer, among others. In one aspect, improved treatments for aP2 mediated disorders are disclosed in which serum aP2 is targeted and the biological activity of aP2 is neutralized or modulated using low-binding affinity aP2 monoclonal antibodies, providing lower fasting blood glucose levels, improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and/or a reduced risk of developing cardiovascular disease.
Abstract translation: 本发明涉及改进的抗αP2抗体和抗原结合剂及其组合物，其靶向脂质伴侣aP2 / FABP4（称为“aP2”），用于治疗疾病如糖尿病，肥胖症，心血管疾病 ，脂肪肝疾病和/或癌症等。 一方面，公开了aP2介导的疾病的改进治疗，其中血清aP2是靶向的，并且使用低结合亲和性aP2单克隆抗体中和或调节aP2的生物学活性，提供较低的空腹血糖水平，改善的全身葡萄糖代谢，增加 全身胰岛素敏感性，脂肪量减少，肝脂肪变性减少，心血管疾病降低和/或发生心血管疾病风险降低。
-
-
-
-
-
-
-
-
-
Search Results
18
records
(took 0.026 seconds)
